Other

(M-002) A Longitudinal Model-based Meta-Analysis (MBMA) of Body Weight in Obesity Trials

(M-012) Considerations for Industry—Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program

(M-016) Integrating Physiologically Based Pharmacokinetic Modeling with Machine Learning for the Rational Design of Nanoparticles to Improve Safety in Biomedical Applications

(M-028) A systematic approach for imputing missing dose information in population pharmacokinetic analysis datasets

(M-036) Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic

(M-093) Challenges in curating Real World Data for modeling: A Bronchopulmonary Dysplasia case study

(M-126) A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages

(M-142) Evaluating concomitant medication use in cystic fibrosis patients using real-world data (RWD) to inform drug-drug interaction risk assessment and clinical trial design of GDC-6988

(T-016) Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development

(T-062) A Pharmacologically-informed Neural Ordinary Differential Equation Framework to Predict Preclinical Pharmacokinetics

(T-114) SAS Macro for Validation of NONMEM Data Items Pertaining to Implicit Expansion of Dose Records in Oral Dose Population Pharmacokinetic Datasets

(T-138) Modeling Patient Risk Factors and their Role in Dose Optimization for Oncological Trials

(W-014) Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients

(W-031) Scientific Project Management (SPM) to Enhance Model-Informed Drug Development

(W-114) Consideration of Study design aspects in the creation of virtual populations for organ impairment studies: One size may not fit all